physIQ Announces Two New Appointments to Executive Leadership Team to Advance Digital Health Market Commercialization
-
John Wilson joins physIQ to drive revenue growth in the life sciences continuum -
Chris Englerth will refine strategy for physIQ brand, advance presence in healthcare and life sciences markets

“We enthusiastically welcome John and Chris. They bring proven performance and well-honed skills to their respective areas of expertise,” said
physIQ’s FDA-cleared, AI-based technology platform uses medical-grade wearable devices to continuously monitor patients in decentralized clinical trials and in hospital at home settings. Through the remote capture of near real-time biosensor data, life sciences and healthcare organizations gain highly personalized, clinically valid, actionable insights to guide drug development and patient care.
In his new role,
“I am privileged to be part of the talented team who helped to pioneer and revolutionize digital health. The continuum between life sciences and healthcare is maturing, and physIQ’s technology converges personalized monitoring with personalized medicine to bring safer, more effective drugs to market faster and help patients live healthier lives,” John said.
John’s credentials span over two decades in sales, solution consulting and operations leadership positions for numerous global companies, including Oracle,
“I am excited to play an integral role building awareness and adoption of our enterprise-ready cloud-based physIQ platform. Proactive, predictive, personalized digital health solutions enhance access to better and more affordable healthcare—yielding benefits for patients, providers, and researchers,” Chris added.
Previously, Chris led global marketing efforts at
About physIQ
physIQ is the leader in digital medicine, dedicated to generating unprecedented health insight using continuous wearable biosensor data and advanced analytics. Its industry-leading, enterprise-ready cloud platform continuously collects and processes data from wearable biosensor using a deep portfolio of FDA-cleared analytics. The company has published one of the most rigorous clinical studies to date in digital medicine and are pioneers in developing, validating, and achieving regulatory approval of Artificial Intelligence-based analytics. With applications in both clinical trial support and healthcare, physIQ is transforming continuous physiological data into insight for health systems, payers, and pharmaceutical companies. For more information, please visit www.physIQ.com. Follow us on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510006064/en/
staci@outlookmarketingsrv.com
847-549-0712
Source: physIQ